Pharmacogenomics implementation: "a little less conversation, a little more action, please"

PharmacogenomicsVol. 24, No. 4 EditorialPharmacogenomics implementation: “a little less conversation, a little more action, please”Kelly E Caudle, James M Hoffman & Roseann S GammalKelly E Caudle *Author for correspondence: Tel.: +1 901 595 3994; E-mail Address: kelly.caudle@stjude.orghttps://orcid.org/0000-0002-5663-3793Department of Pharmacy & Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USASearch for more papers by this author, James M Hoffman https://orcid.org/0000-0002-2625-7766Department of Pharmacy & Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USAOffice of Quality & Patient Safety, St. Jude Children's Research Hospital, Memphis, TN 38105, USASearch for more papers by this author & Roseann S Gammal https://orcid.org/0000-0001-7550-042XDepartment of Pharmacy Practice, Massachusetts College of Pharmacy & Health Sciences, Boston, MA 02115, USASearch for more papers by this authorPublished Online:22 Mar 2023https://doi.org/10.2217/pgs-2023-0020AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: implementationlaboratorypharmacogeneticspharmacogenomicstestingReferences1. Schneider PJ, Pedersen CA, Ganio MC, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: clinical services and workforce – 2021. Am. J. Health Syst. Pharm. 79(18), 1531–1550 (2022).Crossref, Medline, Google Scholar2. Bates DW, Spell N, Cullen DJ et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 277(4), 307–311 (1997).Crossref, Medline, CAS, Google Scholar3. Bates DW, Levine DM, Salmasian H et al. The safety of inpatient health care. N. Engl. J. Med. 388(2), 142–153 (2023).Crossref, Medline, Google Scholar4. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med. 250(3), 186–200 (2001).Crossref, Medline, CAS, Google Scholar5. Chanfreau-Coffinier C, Hull LE, Lynch JA et al. Projected prevalence of actionable pharmacogenetic variants and level A drugs prescribed among US Veterans Health Administration pharmacy users. JAMA Netw. Open 2(6), e195345 (2019).Crossref, Medline, Google Scholar6. Luczak T, Brown SJ, Armbruster D, Hundertmark M, Brown J, Stenehjem D. Strategies and settings of clinical pharmacogenetic implementation: a scoping review of pharmacogenetics programs. Pharmacogenomics 22(6), 345–364 (2021).Link, CAS, Google Scholar7. Empey PE, Pratt VM, Hoffman JM, Caudle KE, Klein TE. Expanding evidence leads to new pharmacogenomics payer coverage. Genet. Med. 23(5), 830–832 (2021).Crossref, Medline, Google Scholar8. Cavallari LH, Pratt VM. Building evidence for clinical use of pharmacogenomics and reimbursement for testing. Clin. Lab. Med. 42(4), 533–546 (2022).Crossref, Medline, Google Scholar9. Caudle KE, Keeling NJ, Klein TE, Whirl-Carrillo M, Pratt VM, Hoffman JM. Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics 19(10), 847–860 (2018).Link, CAS, Google Scholar10. Bank PCD, Caudle KE, Swen JJ et al. Comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clin. Pharmacol. Ther. 103(4), 599–618 (2018).Crossref, Medline, CAS, Google Scholar11. Smith DM, Namvar T, Brown RP et al. Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testing. Pharmacogenomics 21(15), 1085–1094 (2020).Link, CAS, Google Scholar12. Rahawi S, Naik H, Blake KV et al. Knowledge and attitudes on pharmacogenetics among pediatricians. J. Hum. Genet. 65(5), 437–444 (2020).Crossref, Medline, Google Scholar13. Gammal RS, Lee YM, Petry NJ et al. Pharmacists leading the way to precision medicine: updates to the core pharmacist competencies in genomics. Am. J. Pharm. Educ. 86(4), 8634 (2022).Crossref, Medline, Google Scholar14. National Human Genome Research Institute. Inter-Society Coordinating Committee for Practitioner Education in Genomics. https://www.genome.gov/For-Health-Professionals/Inter-Society-Coordinating-Committee-for-Practitioner-Education-in-Genomics (2022).Google Scholar15. Vo TT, Bell GC, Owusu Obeng A, Hicks JK, Dunnenberger HM. Pharmacogenomics implementation: considerations for selecting a reference laboratory. Pharmacotherapy 37(9), 1014–1022 (2017).Crossref, Medline, Google Scholar16. Gaedigk A, Whirl-Carrillo M, Pratt VM, Miller NA, Klein TE. PharmVar and the landscape of pharmacogenetic resources. Clin. Pharmacol. Ther. 107(1), 43–46 (2020).Crossref, Medline, Google Scholar17. Pratt VM, Del Tredici AL, Hachad H et al. Recommendations for clinical CYP2C19 genotyping allele selection: a report of the Association for Molecular Pathology. J. Mol. Diagn. 20(3), 269–276 (2018).Crossref, Medline, CAS, Google Scholar18. Kalman LV, Agundez J, Appell ML et al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin. Pharmacol. Ther. 99(2), 172–185 (2016).Crossref, Medline, CAS, Google Scholar19. Riegert-Johnson DL, Macaya D, Hefferon TW, Boardman LA. The incidence of duplicate genetic testing. Genet. Med. 10(2), 114–116 (2008).Crossref, Medline, Google Scholar20. Gammal RS, Berenbrok LA, Empey PE, Massart MB. Documenting pharmacogenomic test results in electronic health records: practical considerations for primary care teams. J. Pers. Med. 11(12), 1296 (2021).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 24, No. 4 STAY CONNECTED Metrics Downloaded 136 times History Received 6 February 2023 Accepted 15 February 2023 Published online 22 March 2023 Published in print March 2023 Information© 2023 Future Medicine LtdKeywordsimplementationlaboratorypharmacogeneticspharmacogenomicstestingFinancial & competing interests disclosureThis work was funded by the NIH for the Clinical Pharmacogenetics Implementation Consortium (R24GM115264 and U24HG010135). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download